Second phase 3 randomized study to the evaluate efficacy of Squalamine eye drops [OHR-102] and Lucentis injections compared with Lucentis monotherapy in patients with wet age-related macular degeneration

Trial Profile

Second phase 3 randomized study to the evaluate efficacy of Squalamine eye drops [OHR-102] and Lucentis injections compared with Lucentis monotherapy in patients with wet age-related macular degeneration

Planning
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2016

At a glance

  • Drugs Squalamine (Primary) ; Ranibizumab
  • Indications Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Sponsors Ohr Pharmaceutical
  • Most Recent Events

    • 18 Apr 2016 Acording to Ohr Pharmaceuticals media release, this study will provide the data for regulatory approval in major ophthalmic markets worldwide.
    • 29 Mar 2016 According to Ohr Pharmaceutical media release, this trial is being conducted under a Special Protocol Assessment (SPA) with the US FDA.
    • 09 Feb 2016 According to an Ohr Pharmaceutical media release, the trial is expected to begin in the first quarter of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top